干细胞在非血液系统疾病中的应用

胚胎干细胞作为全能干细胞能分化成机体内的任何组织器官,理论上可作为最佳的种子细胞应用于再生医学,但胚胎干细胞的临床应用受道德伦理的争议以及法律的约束,且来源受限。目前临床应用的主要是成体干细胞,这类细胞包括造血干细胞、间充质干细胞、神经干细胞及肝干细胞等。体内和体外实验表明干细胞在一定的条件下可诱导分化成造血细胞、上皮细胞、内皮细胞及神经细胞等,因此成体干细胞可应用于多种临床疾病。本文主要综述成体干细胞在脊髓损伤、脑瘫、外伤性脑损伤、脑卒中、自体免疫性疾病和慢性肝病中的最新研究进展。     

干细胞概述

干细胞是存在于胚胎和成体中的一类特殊细胞,它能长期地自我更新,在特定的条件下具有分化形成多种终末细胞的能力,不同来源的干细胞分化潜能各异。从早期胚胎内细胞团分离的胚胎干细胞能分化形成个体所有的细胞类型,并具有在体外无限增殖的能力,是最具有临床应用前景和研究价值的干细胞之一。在成体各种组织和器官中也存在成体干细胞,用于维持机体结构和功能的稳态。近期有关成体干细胞可塑性的研究和成体组织中多能干细胞存在的证据扩大了人们对成体干细胞分化潜能的认识。干细胞具有的多向分化潜能和自我更新能力使其成为未来再生医学的重要种子细胞,并成为研究人类早期胚层特化和器官形成、药物筛选以及基因治疗的最佳工具。     

成体干细胞的研究及潜在应用

成体干细胞(adultstemcells)存在于人和哺乳动物的多种成体中,具有自我更新和一定的分化潜能.现已从骨髓、软骨、血液、神经、肌肉、脂肪、皮肤、角膜缘、肝脏、胰腺等许多组织中获得干细胞,并在部分成体干细胞的体外分离培养、扩增及诱导分化等研究中取得突破性进展,发现部分成体干细胞具有预想不到的分化潜能.成体干细胞不仅是发育生物学研究的理想模型,而且是细胞移植治疗、人工组织或器官构建的种子细胞和基因治疗的理想载体细胞,因此,在揭示生命的本质和规律及再生医学中有十分广阔的应用前景.     

军事医学科学院干细胞与再生医学研究回顾与展望

干细胞具有高度自我更新、增殖和多向分化潜能,因而成为再生医学的基础.作为中国干细胞研究与应用的＂先驱＂单位和优势单位之一,我院早期开展造血干细胞生物学性能、造血调控机制、造血干/祖细胞扩增和定向诱导分化的研究,取得了一系列重要成果.相继开展的造血干细胞移植等系列研究和应用也取得了突出的成绩.近年来,我院又系统开展了胚胎干细胞自我更新与干性维持机制、干细胞增殖分化调控、干细胞建系与建库技术造血发育调控与造血干细胞移植新策略、成体干细胞治疗、肿瘤干细胞筛选与鉴定、干细胞为种子细胞的三维组织构建、干细胞再生相关药物等多个领域的研究,并取得突出进展进一步我们将瞄准干细胞与再生医学的重大科学问题和关键技术,建立高水平的研究和应用基地,形成我院干细胞与再生医学研究开发的关键技术体系,研发系列具有自主知识产权的关键技术和产品,并培养优秀的科研团队,进入世界先进行列.     

间充质干细胞特性与应用前景

间充质干细胞是中胚层发育的早期细胞,具备干细胞的基本特性。在发育的不同阶段和特定环境条件下,间充质干细胞可向骨、软骨、肌肉、神经、血管及血液细胞等多种方向分化。在成体的很多器官和组织中也存在着间充质干细胞,以备修复和再生所用。间充质干细胞易于体外培养,扩增迅速,可以分化为多种细胞,为干细胞生物工程提供了一个很好的种子细胞。在明确间充质干细胞生物学特性和分化的机制后,可在体外和体内将其定向诱导分化为多种细胞。间充质干细胞具有巨大的临床应用价值和科学研究价值。     

胃肠黏膜G蛋白偶联受体5阳性细胞研究进展

干细胞和再生医学的研究已成为自然科学中最为引人注目的领,人类已在胚胎干细胞、部分成体干细胞如骨髓造血干细胞方面取得进展,但在其他成体干细胞研究,特别是胃肠黏膜干细胞研究领进展甚少.富含亮氨酸重复序列的 G 蛋白偶联受体5(LGR5)是 G 蛋白偶联受体超家族的成,在胃肠黏膜隐窝基底有少量表达,其阳性细胞可在体内分化为胃肠黏膜所有类型的细胞,被认为是可能的胃肠黏膜成体干细胞.LGR5阳性细胞的研究,对组织工程、消化道疾病发病机制研究、干细胞治疗、肿瘤治疗等方面有重要意义.     

成体干细胞肺重建研究进展

成体干细胞来源广泛,无伦理争议,成为近几年的关注热点。研究表明以骨髓来源的间充质干细胞为代表的成体干细胞具有较强的多系分化潜能,可以广泛的参与包括肺在内的受损组织的修复与重建。在动物实验中已观察到,供体来源的成体干细胞可以定向分化为受损肺组织的多种功能细胞,并且有抑制纤维化等病变产生的能力。在本文中,回顾了近年来与肺损伤重建和疾病治疗相关的干细胞研究的最新进展,并探讨了成体干细胞治疗肺疾病与损伤的临床应用前景。     

干细胞与心肌细胞替代治疗

胚胎干细胞及来源于骨髓、骨骼肌、血管、肝脏、皮肤、脂肪等组织器官的成体干细胞均有多向分化潜能。胚胎干细胞可分化为3个胚层的所有组织细胞。成体干细胞具有可塑性和转分化的潜能。在一定条件下,这些干细胞可被诱导分化为心肌细胞。成年心脏可能存在心肌干细胞,具有增殖和分化为包括跳动性心肌细胞的多种细胞的潜能。因此,干细胞可用于心肌细胞替代治疗,以替代死亡的心肌细胞,改善心脏功能,防治心肌梗塞后心衰、减少心肌重构等症状。本文对干细胞治疗心肌梗塞有关进展及问题作一综述。     

骨髓间充质干细胞的免疫学研究进展

间充质干细胞（mesenchymal stem cells,MSCs）是骨髓中除造血干细胞以外的另一种成体干细胞,广泛分布于动物体内骨髓、肝脏、脂肪等多种组织中。MSCS具有强大的自我更新能力和多向分化潜能,是移植领域应用前景广阔的再生来源细胞;同时,MSCs是一种重要的免疫调节细胞,MSCs在炎症细胞因子刺激后对免疫系统表现出很强的抑制作用,所以MSCs有望应用于减少免疫排斥,延长移植物存活时间,治疗相关免疫失调症,如自身免疫疾病等方面。本文主要对间充质干细胞与免疫系统相互作用的研究做相关介绍。     

类器官在发育与再生中的研究进展

类器官(organoid)作为体外模拟器官结构和功能的三维培养体系,已经广泛应用于发育研究、疾病建模和药物筛选。类器官在再生医学中具有重要的应用前景。胚胎干细胞、诱导多能性干细胞和多组织成体干/祖细胞来源的类器官再现了发育分化、稳态自我更新和组织损伤再生过程,为揭示发育和再生调控机制、明确生理病理进程提供了可能。近年来,多细胞类型的新型培养模式和单细胞测序等技术的应用促进了类器官的发展。该文总结了类器官在发育与再生中的最新研究成果,并就前沿技术在类器官研究中的应用进行了综述与展望。     

猪多能干细胞的研究进展

多能干细胞,如胚胎干细胞（embryonic stem cells,ESCs）、诱导多能干细胞（induced pluripotent stem cells,iPSCs）和成体干细胞（adultstemcells,ASCs）,是一类具有巨大潜能的独特细胞。猪作为试验材料,在遗传、代谢、生理生化及基因序列等方面较小鼠更接近于人类,正逐渐成为人类异种移植和再生医学研究的理想生物学模型。然而,目前对猪多能干细胞种类、来源、特征及机制的有限认识直接阻碍了其相关应用。该文将分别对猪ASCs的研究现状、猪类ESCs的分离培养、猪iPSCs的研究进展、多能干细胞间的联系和展望进行论述,以期为从事该领域研究的科研人员提供参考。     

Current evidence on potential of adipose derived stem cells to enhance bone regeneration and future projection

Injuries to the postnatal skeleton are naturally repaired through successive steps involving specific cell types in a process collectively termed “bone regeneration”. Although complex, bone regeneration occurs through a series of well-orchestrated stages wherein endogenous bone stem cells play a central role. In most situations, bone regeneration is successful; however, there are instances when it fails and creates non-healing injuries or fracture nonunion requiring surgical or therapeutic interventions. Transplantation of adult or mesenchymal stem cells (MSCs) defined by the International Society for Cell and Gene Therapy (ISCT) as CD105+CD90+CD73+CD45-CD34-CD14orCD11b-CD79αorCD19-HLA-DR- is being investigated as an attractive therapy for bone regeneration throughout the world. MSCs isolated from adipose tissue, adipose-derived stem cells (ADSCs), are gaining increasing attention since this is the most abundant source of adult stem cells and the isolation process for ADSCs is straightforward. Currently, there is not a single Food and Drug Administration (FDA) approved ADSCs product for bone regeneration. Although the safety of ADSCs is established from their usage in numerous clinical trials, the bone-forming potential of ADSCs and MSCs, in general, is highly controversial. Growing evidence suggests that the ISCT defined phenotype may not represent bona fide osteoprogenitors. Transplantation of both ADSCs and the CD105^- sub-population of ADSCs has been reported to induce bone regeneration. Most notably, cells expressing other markers such as CD146, AlphaV, CD200, PDPN, CD164, CXCR4, and PDGFRα have been shown to represent osteogenic sub-population within ADSCs. Amongst other strategies to improve the bone-forming ability of ADSCs, modulation of VEGF, TGF-β1 and BMP signaling pathways of ADSCs has shown promising results. The U.S. FDA reveals that 73% of Investigational New Drug applications for stem cell-based products rely on CD105 expression as the “positive” marker for adult stem cells. A concerted effort involving the scientific community, clinicians, industries, and regulatory bodies to redefine ADSCs using powerful selection markers and strategies to modulate signaling pathways of ADSCs will speed up the therapeutic use of ADSCs for bone regeneration.     

果蝇干细胞研究进展

本文主要介绍了果蝇五种干细胞,包括生殖干细胞、神经干细胞、造血干细胞、小肠干细胞、肾干细胞及其微环境（niche）的组成成份;简述了五种干细胞系统对应的分子标记;最后重点介绍了调控每种干细胞系统的信号通路。     

Ascl2-Dependent Cell Dedifferentiation Drives Regeneration of Ablated Intestinal Stem Cells

1. Download : Download high-res image (197KB)
2. Download : Download full-size image

     

对比不同类型干细胞对于缺血性脑卒中治疗的研究进展

成人中枢神经系统存在着一定量的神经干细胞,其具有两大关键能力;自我更新和多向分化潜能。缺血性脑卒中是一种由于由脑血流的缺失或减少引起的脑动脉闭塞,进而导致脑组织梗死的脑血管疾病。虽然对于脑损伤的药物治疗已经取得了一定的成果,但目前以干细胞为基础的治疗方法仍成为了研究热点。无论是内源性神经干细胞还是外源性神经干细胞移植均可在脑损伤后向远端损伤区迁移并分化成新的神经细胞,从而在中枢神经系统疾病尤其是脑梗死后进行组织修复和功能恢复。因此在这篇综述中,我们主要探讨不同类型的干细胞对脑梗死介导的脑损伤的应用潜能,对比不同类型干细胞对缺血性脑卒中的治疗优缺点。     

Autophagy in stem cells

Autophagy is a highly conserved cellular process by which cytoplasmic components are sequestered in autophagosomes and delivered to lysosomes for degradation. As a major intracellular degradation and recycling pathway, autophagy is crucial for maintaining cellular homeostasis as well as remodeling during normal development, and dysfunctions in autophagy have been associated with a variety of pathologies including cancer, inflammatory bowel disease and neurodegenerative disease. Stem cells are unique in their ability to self-renew and differentiate into various cells in the body, which are important in development, tissue renewal and a range of disease processes. Therefore, it is predicted that autophagy would be crucial for the quality control mechanisms and maintenance of cellular homeostasis in various stem cells given their relatively long life in the organisms. In contrast to the extensive body of knowledge available for somatic cells, the role of autophagy in the maintenance and function of stem cells is only beginning to be revealed as a result of recent studies. Here we provide a comprehensive review of the current understanding of the mechanisms and regulation of autophagy in embryonic stem cells, several tissue stem cells (particularly hematopoietic stem cells), as well as a number of cancer stem cells. We discuss how recent studies of different knockout mice models have defined the roles of various autophagy genes and related pathways in the regulation of the maintenance, expansion and differentiation of various stem cells. We also highlight the many unanswered questions that will help to drive further research at the intersection of autophagy and stem cell biology in the near future.     

Stem cell therapy: an exercise in patience and prudence

In recent times, the epigenetic study of pluripotency based on cellular reprogramming techniques led to the creation of induced pluripotent stem cells. It has come to represent the forefront of a new wave of alternative therapeutic approaches in the field of stem cell therapy. Progress in drug development has saved countless lives, but there are numerous intractable diseases where curative treatment cannot be achieved through pharmacological intervention alone. Consequently, there has been an unfortunate rise in incidences of organ failures, degenerative disorders and cancers, hence novel therapeutic interventions are required. Stem cells have unique self-renewal and multilineage differentiation capabilities that could be harnessed for therapeutic purposes. Although a number of mature differentiated cells have been characterized in vitro, few have been demonstrated to function in a physiologically relevant context. Despite fervent levels of enthusiasm in the field, the reality is that other than the employment of haematopoietic stem cells, many other therapies have yet to be thoroughly proven for their therapeutic benefit and safety in application. This review shall focus on a discussion regarding the current status of stem cell therapy, the issues surrounding it and its future prospects with a general background on the regulatory networks underlying pluripotency.     

Induced pluripotent stem (iPS) cells from human fetal stem cells (hFSCs)

Introduction

(1) Human embryonic stem (ES) cells are pluripotent but are difficult to be used for therapy because of immunological, oncological and ethical barriers. (2) Pluripotent cells exist in vivo, i.e., germ cells and epiblast cells but cannot be isolated without sacrificing the developing embryo. (3) Reprogramming to pluripotency is possible from adult cells using ectopic expression of OKSM and other integrative and non-integrative techniques. (4) Hurdles to overcome include i.e stability of the phenotype in relation to epigenetic memory.

Sources of data

We reviewed the literature related to reprogramming, pluripotency and fetal stem cells.

Areas of agreement

(1) Fetal stem cells present some advantageous characteristics compared with their neonatal and postnatal counterparts, with regards to cell size, growth kinetics, and differentiation potential, as well as in vivo tissue repair capacity. (2) Amniotic fluid stem cells are more easily reprogrammed to pluripotency than adult fibroblast. (3) The parental population is heterogeneous and present an intermediate phenotype between ES and adult somatic stem cells, expressing markers of both.

Areas of controversy

(1) It is unclear whether induced pluripotent stem (iPS) derived from amniotic fluid stem cells are fully or partially reprogrammed. (2) Optimal protocols to ensure highest efficiency and phenotype stability remains to be determined. (3) The “level” of reprogramming, fully vs partial, of iPS derived from amniotic fluid stem cells remain to be determined.

Growing points

Banking of fully reprogrammed cells may be important both for (1) autologous and allogenic applications in medicine, and (2) disease modeling.